Drug-induced systemic lupus erythematosus associated with etanercept therapy
Drug-induced systemic lupus erythematosus associated with etanercept therapy
复制标题
DOI：
10.1016/s0140-6736(02)07714-0
复制
发表时间：
2002-02-16
期刊：
影响因子：
168.9
通讯作者：
Block, JA
中科院分区：
文献类型：
--
作者：
Shakoor, N;Michalska, M;Block, JA
肿瘤坏死因子（TNF）-α的特异性拮抗剂已迅速普及用于治疗类风湿性关节炎。针对TNF-α的单克隆抗体英夫利西单抗与系统性红斑狼疮（SLE）的诱导相关;然而，尚未发表与可溶性TNF-α受体依那西普相关的药物诱导SLE的报告。我们描述了4例女性患者在依那西普治疗过程中出现SLE的体征和症状，其中2例SLE明确。诊断为SLE后，停用依那西普，SLE相关症状迅速消退。依那西普应列入药物诱导的SLE相关药物列表。
Specific antagonists of tumour necrosis factor (TNF)-alpha have rapidly gained popularity for the treatment of rheumatoid arthritis. The monoclonal antibody against TNF-alpha, infliximab, has been associated with induction of systemic lupus erythematosus (SLE); however, there have been no published reports of drug-induced SLE associated with the soluble TNF-alpha receptor etanercept. We describe four female patients who developed signs and symptoms of SLE during treatment with etanercept; in two SLE was unambiguous. On diagnosis of SLE, etanercept was discontinued and the SLE-related symptoms promptly resolved. Etanercept should be considered in the list of agents associated with drug-induced SLE.